LPL Financial’s Cardiol Therapeutics CRDL Stock Holding History

LPL Financial’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.4K	Buy	+12,610	New	+$16K	﹤0.01%	6150
2025 Q3	–	Sell	-15,210	Closed	-$20.7K	–	5842
2025 Q2	$20.7K	Buy	+15,210	New	+$17.7K	﹤0.01%	5470
2025 Q1	–	Sell	-18,310	Closed	-$23.4K	–	5388
2024 Q4	$23.4K	Buy	18,310 +5,000	+38%	+$8.43K	﹤0.01%	5180
2024 Q3	$26.4K	Buy	+13,310	New	+$27.6K	﹤0.01%	5061
2022 Q3	–	Sell	-10,230	Closed	-$14K	–	4435
2022 Q2	$14K	Buy	+10,230	New	+$14.6K	﹤0.01%	4369

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial's CRDL Position: Q2 2026 in Review

LPL Financial opened a new position in Cardiol Therapeutics (CRDL) in Q2 2026: 12,610 shares worth $13.4K. The stake represents ﹤0.01% of the portfolio and ranks #6150 among its holdings. This is a return to the name: LPL Financial previously reported a position in CRDL as recently as Q2 2025.

LPL Financial first reported a position in CRDL in Q2 2022 and has held it in 5 quarters since. The position peaked at $26.4K in Q3 2024. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

LPL Financial held 12,610 shares of Cardiol Therapeutics worth $13.4K as of Q2 2026.
Cardiol Therapeutics was a new LPL Financial position in Q2 2026.
Cardiol Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #6150 holding.
LPL Financial first reported a position in Cardiol Therapeutics in Q2 2022 and has held it in 5 quarters since.
LPL Financial's Cardiol Therapeutics position peaked at $26.4K in Q3 2024.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.